Table 1

Study characteristics.

First author, year

Centers

Population

Primary endpoint

Comparator regimen

Minimum doses


Chastre, 2008 [39]

M

VAP

C/M success

Doripenem

1

Yanagihara, 2005 [40]

S

CAP

C/M success

Sulbactam/ampicillin

6

Schmit, 2006 [41]

M

NP

Clinical response

Piperacillin/tazobactam

1

Joshi, 2006 [42]

M

NP

Clinical response

Piperacillin/tazobactam

1

Romanelli, 2006 [43]

M

CAP

C/M success

Meropenem

NR

Shorr, 2005 [44]

M

VAP

Clinical success

Levofloxacin/ceftazidime

NR

Zanetti, 2003 [45]

M

NP

C/M success

Cefepime

NR

West, 2003 [46]

M

NP

C/M success

Levofloxacin/ceftazidime

1

Torres, 2000 [47]

M

VAP

C/M success

Ciprofloxacin

1

Bartoloni, 1999 [48]

M

CAP

Clinical response

Meropenem

Jaccard, 1998 [49]

M

Mixed

Clinical success

Piperacillin/tazobactam

5

Marra*, 1998 [50]

S

Mixed

C/M success, resistance

Piperacillin/tazobactam

1

Ho, 1997 [51]

NR

CAP

Clinical success

Ceftazidime

NR

Raad, 1996 [52]

S

Mixed

C/M success

Aztreonam/vancomycin

NR

Vic, 1996 [53]

S

Mixed

Bacteriological parameters

Ceftazidime/amikacin

NR

Bohme, 1995 [54]

NR

Mixed

C/M success

Ceftazidime/piperacillin

NR

Siami, 1995 [55]

M

CAP & NP

Safety

Ciprofloxacin

15

Cometta, 1994 [56]

M

Mixed

Tolerance

Imipenem/netilmycin

NR

Fink, 1994 [57]

M

CAP & NP

C/M success

Ciprofloxacin

1

Norrby, 1993 [58]

M

Mixed

C/M success

Ceftazidime

NR


M: multicenter, S: single center, NR: not reported, C/M: clinical/microbiological, VAP: ventilator-associated pneumonia, CAP: community-acquired pneumonia, ICU: intensive care unit, NP: nosocomial pneumonia, NR: not reported, CF: cystic fibrosis, PA: Pseudomonas aeruginosa

*Although this study did not explicitly report on PA outcomes, it was included because it was one of the few studies specifically reporting zero incidence of C. difficile diarrhea

Zilberberg et al. BMC Pulmonary Medicine 2010 10:45   doi:10.1186/1471-2466-10-45

Open Data